Capozide 25/15
Drug - Capozide 25/15
The trade name of the product as shown on the labeling.
Dosage -
TABLET; ORAL
The product dosage form and route separated by a semi-colon.
Active Ingredient(s) -
Captopril; Hydrochlorothiazide
Multiple ingredients are in alphabetical order.
Strength -
25MG;15MG
The potency of the active ingredient(s), Captopril; Hydrochlorothiazide. May repeat for multiple part products.
Applicant -
APOTHECON
The firm name holding legal responsibility for Capozide 25/15. The firm name is condensed to a maximum twenty character unique string.
New Drug Application (NDA) Number -
018709
The FDA assigned number to Capozide 25/15. Format is nnnnnn.
Product Number -
001
The FDA assigned number to identify Capozide 25/15. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
Therapeutic Equivalence (TE) Code -
AB
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.
Approval Date -
Oct 12, 1984
The date Capozide 25/15 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".
Reference Listed Drug (RLD) -
No
The pioneer or innovator of Capozide 25/15. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.
Type -
RX
The group or category of approved drugs Capozide 25/15 is in. Format is RX, OTC, DISCN.
Applicant Full Name -
Apothecon Inc Div Bristol Myers Squibb
The full name of the firm holding legal responsibility for the new application of Capozide 25/15.
Capozide 25/15
|